ArticleMolecular diagnosis & therapy2012
PARP1 polymorphisms increase the risk of gastric cancer in a Chinese population.
Article in Molecular diagnosis & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Multi-omics analysis of parthanatos related molecular subgroup and prognostic model development in stomach adenocarcinoma.PloS one · 2025Article
- Mutations in Helicobacter pylori infected patients with chronic gastritis, intestinal type of gastric cancer and familial gastric cancer.Hereditary cancer in clinical practice · 2024Article
- Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.International journal of cancer · 2018Article
- High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer.Oncology letters · 2016Article
- Expression of cluster of differentiation-95 and relevant signaling molecules in liver cancer.Molecular medicine reports · 2015Article
- Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.Molecular aspects of medicine · 2013Review
- Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population.BMC cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivePoly(adenosine diphosphate [ADP]-ribose) polymerase 1 (PARP1), a protein involved in the DNA repair mechanism, plays an important role in carcinogenesis. In this study, we investigated whether single nucleotide polymorphisms of PARP1 contribute to gastric cancer (GC) and its precursor lesions (gastric precancerous lesions; GPL) in a case-control study conducted in the Hexi area of China, a high-risk area for GC.
methodsPARP1 162C>G (Phe54Leu) and 2819A>G (Lys940Arg) polymorphisms were genotyped by real-time PCR using a TaqMan assay in 140 GC cases, 110 GPL cases, and 120 controls. Data were statistically analyzed using the chi-squared test and a logistic regression model.
resultsThe presence of the PARP1 2819G allele was associated with an increased risk of GC (odds ratio [OR] 2.354; 95% CI 1.140, 4.861; p = 0.018), especially for cardia GC and diffuse-type GC (ORs 2.988 and 3.784, respectively). We also observed an interaction between Helicobacter pylori infection, GC family history, and the presence of the PARP1 2819G allele. In contrast, the PARP1 162C>G polymorphism was not significantly associated with GPL or GC.
conclusionThe study suggests that the PARP1 2819G allele is associated with an increased risk of GC. In addition, H. pylori-positive status and family history jointly contribute to a higher risk of GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.